|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chinese Society of Clinical Oncology(CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021(English version)显示文摘1. General guidelines2. Diagnosis3. Staging4. Treatment4.1 Diffuse large B-cell lymphoma(DLBCL)4.2 Follicular lymphoma(FL)4.3 Mantle cell lymphoma(MCL)4.4 Marginal zone lymphoma(MZL)4.5 Burkitt lymphoma(BL)4.6 CLL/Small lymphocytic lymphoma(SLL)4.7 Extra-nodal natural killer/T-cell lymphoma(ENKTCL), nasal type4.8 Peripheral T-cell lymphoma(PTCL)4.9 HL4.10 Primary central nervous system lymphoma5. Prognosis Lymphomas are a group of heterogeneous diseases. | Jun Zhu Jun Ma Union for China Lymphoma Investigators of Chinese Society of Clinical Oncology Zhixiang Shen Zifen Gao Huiqiang Huang Xiaoqiu Li Yexiong Li Lugui Qiu Weili Zhao Qingyuan Zhang | 2021 | Chinese Journal of Cancer Research2021，33，3： | 18 |
| 2 | ADC值对食管癌T分期及病理分级的诊断价值显示文摘目的探讨ADC值与食管癌T分期及病理分级的关系。材料与方法收集经病理证实的初诊食管癌患者,术前均行常规MRI及弥散加权成像(diffusion weighed imaging,DWI)扫描,根据食管癌MRI分期、病理分级、有无淋巴结转移等进行分组,测量食管癌原发灶的平均ADC值,对其与MRI分期、病理分级、有无淋巴结转移的相关性进行统计分析。结果食管癌平均ADC值与T分期呈负相关(r=-0.645,P<0.01),随着肿瘤T分期的增加,ADC值呈逐渐减小趋势。低分化组平均ADC值小于中-高分化组,中-高组平均ADC值为(1.8514±0.40295)×10^-3 mm^2/s,低分化组患者平均ADC值为(1.7125±0.37767)×10^-3 mm^2/s,不同分化程度两组间平均ADC值差异不具有统计学意义(P=0.683)。结论ADC值对食管癌T分期有重要意义,可以在术前或是综合治疗之前为临床对肿瘤分期及分化程度预测提供量化指标,从而为临床治疗提供帮助。 | 孙静 王铸 | 2020 | 磁共振成像2020，11，7： | 6 |
| 3 | 3.0T MRI对新辅助化疗后食管癌术前T分期的准确性及组织病理学相关性显示文摘目的:探讨3.0T磁共振成像对新辅助化疗食管癌术前T分期及组织病理学分期一致性的价值。方法:前瞻性纳入2017年1月至2018年12月期间79例食管癌患者。患者均接收2周期新辅助化疗后再接收3.0T MRI检查及根治性手术。2位不同的阅片人员分别对T2加权TSE BLADE、增强StarVIBE、高分辨率StarVIBE延迟扫描上病灶T分期进行判断。结果:新辅助化疗结束至MRI检查间隔时间为(23±2)d。在T2加权TSE BLADE扫描中,2位阅片人的判断准确性最高(κ=0.810,P<0.0001)。T2加权TSE BLADE、增强StarVIBE、高分辨率StarVIBE延迟扫描对术后组织病理学T分期的诊断准确率分别为86.1%~96.2%,86.1%~94.9%,86.1%~96.2%。高分辨率StarVIBE延迟扫描在对T0,T1,T2,T4的判断价值最高,而T2加权TSE BLADE对T3病变的判断价值最高。结论:除T3期病变外,T2加权TSE BLADE序列在明确新辅助化疗后食管癌病变T分期方面具有更高的精准度。T2加权TSE BLADE、增强StarVIBE和高分辨率StarVIBE延迟扫描三者联合不能进一步提高诊断准确性。 | 赵峰 朱军 郭楠楠 刘燕文 | 2019 | 临床与病理杂志2019，39，12： | 5 |
| 4 | 食管鳞癌术后化疗与副作用关联性显示文摘目的探讨食管鳞癌(esophageal squamous cell carcinoma,ESCC)术后化疗方案与预后生存及副作用的关系。方法收集2014年6月―2018年11月18日于福建医科大学附属第一医院、福建省肿瘤医院就诊的ESCC患者病例,根据明确的纳入和排除标准,最终纳入188例。使用Kaplan-Meier法计算累计生存概率,log-rank进行组间差异比较,Cox回归分析生存影响因素,应用多组独立样本秩和检验比较化疗方案组间的副作用,采用非条件Logistic回归分析模型分析化疗方案与ESCC术后副作用的相关性。结果化疗方案是ESCC预后的影响因素,其中'多西他赛(docetaxel,DOC)+洛铂(luoplatinum,LBP)/奥沙利铂(oxaliplatin,OXA)'、'紫杉醇(paclitaxel,PTX)+LBP/OXA'化疗方案总生存期均优于'DOC+顺铂(cisplatin,DDP)/奈达铂(nedaplatin,NDP)'组化疗方案;化疗方案与ESCC术后出现的血液/骨髓异常等副作用相关(χ~2=11.741,P=0.008),'DOC+LBP/OXA'组较'DOC+DDP/NDP'组化疗方案,会增加白细胞降低发生的风险(OR=4.089,95%CI:1.073~15.585,P=0.039),减少淋巴细胞水平降低发生的风险(OR=0.257,95%CI:0.075~0.878,P=0.030)。结论化疗方案是ESCC术后预后生存及副作用的影响因素,'DOC+LBP/OXA'、'PTX+LBP/OXA'两组化疗方案的预后生存情况优于'DOC+DDP/NDP'化疗方案;'DOC+LBP/OXA'化疗方案相对其它方案可降低副作用的发生风险。 | 李姗姗 林征 马明阳 苏昆卉 陈雅婷 刘永兰 胡志坚 | 2020 | 中华疾病控制杂志2020，24，7： | 4 |
| 5 | Comments on Chinese guidelines for diagnosis and treatment of malignant lymphoma 2018(English version)显示文摘Lymphoid and myeloid neoplasms are common malignant tumors in China,which threaten people’s health(1).To improve the diagnosis and treatment of lymphoma,the National Health Commission of the People’s Republic of China revised Chinese guidelines for diagnosis and treatment of malignant lymphoma in 2018(2).The new guidelines are based on the Classification of Tumours of Haematopoietic and Lymphoid Tissues revised by the World Health Organization in 2016.The new edition provided principles of accurate pathological diagnosis of lymphoma on the basis of various scales including histomorphology,immunohistochemistry,fluorescent immunohybridization and genetics. | Weiping Liu Jun Zhu | 2019 | Chinese Journal of Cancer Research2019，31，5： | 4 |
| 6 | Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives显示文摘Classical Hodgkin lymphoma(cHL) has been identified with universal genetic alterations of chromosome 9p24.1,which contains PD-L1/PD-L2 genes.The amplification of 9p24.1 is associated with the increased expression of PDL1 and PD-L2 on RS cells, which promotes their immune evasion, and subsequently makes cHL sensitive to PD-1 blockade.Several PD-1 inhibitors have shown significant efficacies with overall response rate(ORR) of 70%-90% in relapse/refractory(r/r) cHL and have acquired the approvals for this indication.Recently, more and more studies are conducted to investigate PD-1 blockade in earlier disease course and in combination with neo-agents or chemotherapy.Unlike cHL, non-Hodgkin lymphoma(NHL) consists of numerous subtypes harboring highly biological heterogeneity.Only a few subtypes have been shown to have genetic alteration of 9p24.1 including primary mediastinal B cell lymphoma(PMBL), gray zone lymphoma(GZL) with features intermediate between diffuse large B cell lymphoma(DLBCL) and cHL, primary central nervous system lymphoma(PCNSL) and primary testicular lymphoma(PTL).Epstein-Barr virus(EBV)-associated lymphomas have a virally mediated overexpression of PD-L1, also making them sensitive to PD-1 blockade.Therefore, PD-1 inhibitors are less effective in most r/r NHL than in r/r cHL.Further understanding of the biological features of NHL and immune checkpoint inhibitors(ICPi) combined therapy is the research focus in the future.In this review, we outlined the recent progress of ICPi in lymphoma originating from clinical studies. | Ningjing Lin Yuqin Song Jun Zhu | 2020 | Chinese Journal of Cancer Research2020，32，3： | 3 |
| 7 | SOX11抑制食管癌细胞增殖和迁移的机制研究显示文摘目的探讨转录因子SOX11在食管癌组织和细胞系中的表达及对人食管癌细胞EC109增殖和迁移的影响,并初步探讨其作用机制。方法qRT-PCR和免疫组织化学法分析SOX11在食管癌组织、细胞系(EC109、KYSE150、KYSE410和KYSE510)及正常食管上皮细胞HEEC的表达;分别转染pcDNA3.1(+)-Flag-SOX11质粒(实验组)和pcDNA3.1(+)-Flag-Vector质粒(对照组)至EC109细胞系,qRT-PCR验证SOX11的过表达;CCK-8实验和Transwell实验分析SOX11对细胞增殖和迁移能力的影响;qRT-PCR及Western blot验证SOX11对细胞增殖和迁移的相关标志物表达分析。结果与食管上皮组织相比,SOX11 mRNA和蛋白在食管癌组织中的表达明显下调;SOX11的蛋白表达下调与肿瘤分级(P=0.014)、T分期(P=0.036)、淋巴结转移(P=0.014)相关;同时与食管上皮细胞相比,SOX11 mRNA在食管癌细胞中表达下调,差异具有统计学意义(P<0.001);与对照组相比,实验组24、48、72 h细胞活性受到明显抑制(P<0.05);实验组细胞迁移能力明显受到抑制(P<0.001);与对照组相比,实验组中active-β-catenin及下游的基因受到了明显的抑制。结论SOX11在人食管癌组织和细胞系中表达下调,可能通过拮抗Wnt/β-catenin信号通路参与食管癌的进程。 | 赵楠楠 秦文 韩永焕 鲁静 李亚敏 徐亚君 | 2020 | 实用肿瘤学杂志2020，34，1： | 3 |
| 8 | Chidamide combined with cyclophosphamide,doxorubicin,vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma显示文摘Objective:Chidamide is an oral histone deacetylase subtype-selective inhibitor approved for relapsed or refractory peripheral T-cell lymphoma(PTCL).This phase 1 b study evaluated the safety,pharmacokinetics,and preliminary efficacy of chidamide in combination with cyclophosphamide,doxorubicin,vincristine and prednisone(CHOP)for treatment-na?ve PTCL patients.Methods:This study was an open-label,multicenter trial composed of dose escalation and dose expansion.Patients received CHOP for six 21-d cycles and chidamide on d 1,4,8 and 11 in each cycle.Four dose levels of chidamide(20,25,30 and 35 mg)were evaluated.The primary objective was to evaluate the safety and tolerability of the combination regimen.Results:A total of 30 patients were evaluated in this study:15 in the dose-escalation part and 15 in the doseexpansion part.In the dose-escalation study,three patients were enrolled in the 35 mg chidamide cohort.One had dose-limiting toxicity with grade 3 vascular access complications,and one had grade 2 neutropenia with a sustained temperature>38°C.Dose escalation was stopped at this chidamide dose level.The most common(≥10%)grade 3 or 4 adverse events(AEs)were leukopenia(90.0%),neutropenia(83.3%),vomiting(13.3%),thrombocytopenia(10.0%)and febrile neutropenia(10.0%).No significant changes in chidamide pharmacokinetic properties were observed before and after combination treatment.The objective response rate for the 28 patients evaluable for preliminary efficacy was 89.3%(25/28),with 16(57.1%)achieving complete response or unconfirmed complete response.The estimated median progression-free survival was 14.0 months.In summary,we chose chidamide 30 mg as the recommended dose for phase 2.Conclusions:The addition of chidamide to standard CHOP chemotherapy was tolerable with promising preliminary efficacy in previously untreated PTCL patients,which supports further clinical studies with this combination regimen for the frontline treatment of PTCL. | Lin Gui Junning Cao Dongmei Ji Huilai Zhang Qian Fan Jun Zhu Yuqin Song Shiyu Jiang Zhiqiang Ning Jia Yu Yuankai Shi | 2021 | Chinese Journal of Cancer Research2021，33，5： | 3 |
| 9 | 皮肤黑色素瘤的临床病理特征及预后显示文摘目的探讨皮肤黑色素瘤患者的临床病理特征及预后。方法收集2008年2月至2019年8月于华中科技大学同济医学院附属同济医院治疗的皮肤黑色素瘤患者的临床病理资料,生存分析采用Kaplan-Meier法和Log rank检验,影响因素分析采用Cox比例风险回归模型。结果125例患者中,Ⅰ期12例,Ⅱ期62例,Ⅲ期30例,Ⅳ期21例;肢端型76例,非肢端型49例。全组患者中位总生存时间(OS)为44个月,1、2、5年生存率分别为85.4%、63.2%和38.7%。卡氏体力状态评分、肿瘤分期、原发灶部位、脉管浸润、ki-67指数、BRAF基因、术前乳酸脱氢酶(LDH)水平、手术治疗与患者预后有关(均P<0.05)。接受干扰素治疗患者的中位OS(53个月)优于未接受干扰素治疗的患者(40个月,P=0.448);Ⅲ期患者中,接受干扰素治疗患者的中位OS(40个月)优于未接受干扰素治疗的患者(17个月,P=0.012)。Ⅱ期患者中,肢端型患者1、2、5年生存率分别为97.1%、84.7%和65.8%,非肢端型患者1、2、5年生存率分别为93.3%、70.0%和17.0%;Ⅱ期肢端型患者预后优于非肢端型患者(P=0.043)。Ⅲ期患者肢端型中位OS(32个月)优于非肢端型患者(17个月,P=0.164)。Ⅳ期患者肢端型中位OS(8个月)短于非肢端型患者(11个月,P=0.458)。肿瘤分期及术前LDH水平为皮肤黑色素瘤患者预后的独立危险因素(均P<0.05)。结论干扰素治疗可以改善Ⅲ期患者预后,Ⅱ期肢端型患者预后优于非肢端型患者,肿瘤分期及术前LDH水平为皮肤黑色素瘤患者预后的独立危险因素。 | 田勇 李孟伟 刘起昆 康皓 | 2022 | 中华肿瘤杂志2022，44，10： | 2 |
| 10 | Management guidelines for esophageal carcinoma 2018: Chinese standards in clinical practice显示文摘Esophageal carcinoma is now the sixth most common cause of cancer-related deaths worldwide. China, unfortunately, locates in the highest-risk area (often referred to as the “esophageal cancer belt”) spanning from northern Iran through the Central Asian republics and into northern China. The high prevalence areas spread from south to north in China. In the highest prevalence areas, the crude incidence of esophageal cancer can even reach more than 100/100,000, nearly 7 times that of the whole country. More than 210,000 patients die from esophageal cancer in China every year, accounting for half of the esophageal cancer-related death worldwide. It is currently one of the most threatening cancers for Chinese people. | Yuan Feng Nan Wu | 2019 | Chinese Journal of Cancer Research2019，31，3： | 2 |
| 11 | 云南省肿瘤医院1203例黑色素瘤临床分析显示文摘目的探讨昆明医科大学第三附属医院确诊黑色素瘤发病特点,为云南省黑色素瘤防治提供参考。方法收集2007年1月至2021年12月在昆明医科大学第三附属医院/云南省肿瘤医院确诊的黑色素瘤患者临床资料,对患者性别、年龄、发病部位及其相互间的关系、发病趋势进行分析。结果1203例黑色素瘤患者中77.3%原发于皮肤,17.3%原发于黏膜。患者年龄11~90岁,31~70岁年龄段患病人数最多(82.8%)。肢端皮肤黑色素瘤多见于男性;生殖系统黏膜黑色素瘤多见于女性(P<0.05)。头颈黏膜黑色素瘤占全身黏膜黑色素瘤的55.3%,头颈黏膜黑色素瘤的比例高出全身其他部位黏膜黑色素瘤比例5.58倍。结论云南省肿瘤医院黑色素瘤就诊率呈上升趋势。云南省黑色素瘤防治重点为四肢和头颈部黑色素瘤,特别是头颈部黏膜黑色素瘤。 | 张海霞 李磊 金磊 叶沛婧 孙传政 | 2022 | 昆明医科大学学报2022，43，8： | 2 |
| 12 | 常见皮肤肿瘤的诊断与治疗进展显示文摘皮肤肿瘤分为良性肿瘤与恶性肿瘤。常见的良性肿瘤有细胞痣、先天性血管瘤、疤痕疙瘩等,良性肿瘤一般对人体危害不大,而皮肤恶性肿瘤如基底细胞癌、鳞状细胞癌、恶性黑色素瘤等可发生浸润、转移,严重影响人类健康。本综述主要阐述常见皮肤恶性肿瘤的诊断与治疗进展,总结皮肤恶性肿瘤的诊治新方法、新技术,以期为皮肤恶性肿瘤的诊断、治疗提供参考。 | 张晓容(综述) 熊霞 徐基祥(审校) | 2020 | 肿瘤预防与治疗2020，33，12： | 2 |
| 13 | Ivor-Lewis术式与Sweet术式治疗胸段食管癌的疗效比较显示文摘目的:评价右胸、上腹部两切口(Ivor-Lewis术式)、左胸一切口(Sweet术式)两种术式治疗胸段食管癌的安全性、近期及远期疗效。方法:对2007年7月至2011年7月间我院收治351例经手术切除的食管癌患者进行回顾性分析,其中129例患者经Ivor-Lewis术式食管癌根治术,222例经Sweet术式食管癌根治术,分别对两组患者围手术期情况及远期生存进行对比分析。结果:Ivor-Lewis及Sweet术式食管上切缘阳性率分别为1.6%、6.8%;心率失常发生率分别为4.7%、11.7%;平均清扫淋巴结数分别为(16.15±6.41)个、(13.19±7.26)个;平均转移淋巴结数分别为(1.95±2.49)个、(1.31±2.21)个;胸部淋巴结转移率分别为24.0%、14.4%,上述差异均有统计学意义(P<0.05);而在平均手术出血量、术后平均住院时间、术后肺部并发症、吻合口瘘、呼吸衰竭、膈疝、吻合口出血发生率无统计学差异(P>0.05);Ivor-Lewis术及Sweet术后1、3、5年生存率分别是81.7%、51.0%、37.5%和81.0%、48.3%、31.8%,差异无统计学意义(P=0.691);单因素分析发现肿瘤大小、浸润深度、淋巴结转移部位、淋巴结转移数量、病理分期、神经脉管浸润、围手术期输血是影响预后的因素(P<0.05),Cox分析发现肿瘤病理分期、淋巴结转移数目、神经脉管浸润、围手术期输血是影响食管癌患者预后的独立危险因素。结论:Ivor-Lewis术式较Sweet术式切缘阳性率低、淋巴结清扫更彻底、心率失常发生率低,具有一定优势,但在远期生存率上并无明显差异。 | 杨刚华 张雷 王林 袁达伟 党诚学 张毓萍 | 2021 | 现代肿瘤医学2021，29，24： | 2 |
| 14 | Comments on Chinese guidelines for diagnosis and treatment of melanoma 2018(English version)显示文摘Melanoma is a rare malignant tumor in China;however,its mortality rate is high and the incidence rate is also increasing year by year.In order to improve the efficacy of melanoma treatment,the National Health Commission of the People’s Republic of China revised Chinese guidelines for diagnosis and treatment of melanoma in 2018,and meanwhile its modified English version Chinese guidelines for diagnosis and treatment of melanoma 2018(English version)(1)is also published.Based on the most updated research findings for the Chinese ethnicity with emphasis on acral and mucosal melanomas,two most commonly seen subtypes in Asia,as well as treatment for melanoma liver metastases. | Xue Bai Lili Mao Jun Guo | 2019 | Chinese Journal of Cancer Research2019，31，5： | 1 |
| 15 | 钡餐造影及CT扫描在食管癌患者术前分期评估中的临床价值显示文摘目的探讨钡餐造影及电子计算机断层扫描(CT)在食管癌患者术前分期评估中的临床价值。方法选取2019年6月至2020年6月民权县人民医院收治的65例食管癌患者,均行X线钡餐造影及CT检查。比较两种方法诊断食管癌分期检出率及二者联合检查食管癌的分期准确度,采用Kappa分析二者单独及联合检查与病理检查结果的一致性。结果X线钡餐造影对早期食管癌的检出率明显高于CT检查(P<0.05),中晚期食管癌检出率明显低于CT检查(P<0.05);X线钡餐造影分期诊断结果与病理检查结果不具有一致性(Kappa=0.048),CT检查与病理检查结果一致性差(Kappa=0.100),二者联合检查与病理检查结果一致性较好(Kappa=0.738);X线钡餐造影、CT检查及二者联合检查诊断食管癌Ⅰ~Ⅱ期准确度比较差异无统计学意义(P>0.05),而二者联合检查诊断食管癌Ⅲ~Ⅳ期准确度明显高于单独检查(P<0.05)。结论X线钡餐造影在早期食管癌诊断价值较高,CT检查在中晚期食管癌诊断中价值较高,二者联合检查可提高食管癌Ⅲ~Ⅳ期诊断准确度,对临床食管癌的分期诊断有较高的参考价值。 | 王建华 王发权 胡涛 | 2021 | 食管疾病2021，3，4： | 1 |
| 16 | 食管癌患者围手术期健康教育研究进展显示文摘基于食管癌手术患者并发症多、生活质量差等特征,健康教育在改善患者围手术期早期活动、肺部康复、饮食管理、自我照护行为等方面发挥重要作用。本研究从食管癌手术患者健康教育内容、方式及质量评价指标等方面对国内外相关文献进行综合分析与归纳。旨在改善食管癌手术患者围手术期的知信行现状,降低围手术期并发症的相关风险、促进患者快速康复方面提供借鉴思路。 | 翁慧 吴德全 | 2021 | 当代护士(上旬刊)2021，28，8： | 1 |
| 17 | Endoscopic submucosal tunnel dissection for early esophageal squamous cell carcinoma in patients with cirrhosis:A propensity score analysis显示文摘BACKGROUND Although early esophageal squamous cell carcinoma(EESCC)with cirrhosis is a relatively rare clinical phenomenon,the management of EESCC in cirrhotic patients continues to be a challenge.AIM To evaluate the feasibility,safety,efficacy and long-term survival outcomes of endoscopic submucosal tunnel dissection(ESTD)for treating EESCC in patients with cirrhosis.METHODS This was a single-center retrospective cohort study.We examined 590 EESCC patients who underwent ESTD between July 14,2014,and May 26,2021,from a large-scale tertiary hospital.After excluding 25 patients with unclear lesion areas or pathological results,the remaining 565 patients were matched at a ratio of 1:3 by using propensity score matching.A total of 25 EESCC patients with comorbid liver cirrhosis and 75 matched EESCC patients were ultimately included in the analysis.Parametric and nonparametric statistical methods were used to compare the differences between the two groups.The Kaplan–Meier method was used to create survival curves,and differences in survival curves were compared by the log-rank test.RESULTS Among 25 patients with liver cirrhosis and 75 matched noncirrhotic patients,there were no significant differences in intraoperative bleeding(P=0.234),30-d post-ESTD bleeding(P=0.099),disease-specific survival(P=0.075),or recurrence-free survival(P=0.8196).The mean hospitalization time and costs were significantly longer(P=0.007)and higher(P=0.023)in the cirrhosis group than in the noncirrhosis group.The overall survival rate was significantly lower in the cirrhosis group(P=0.001).CONCLUSION ESTD is technically feasible,safe,and effective for patients with EESCC and liver cirrhosis.EESCC patients with Child-Pugh A disease seem to be good candidates for ESTD. | Lin-Lin Zhu Li-Xia Liu Jun-Chao Wu Tao Gan Jin-Lin Yang | 2022 | World Journal of Clinical Cases2022，10，31： | 1 |
| 18 | 贝伐珠单抗治疗对放射性脑损伤患者MR-T_(1ρ)和脑结构MRI的影响探究显示文摘目的:探讨贝伐珠单抗(BVZ)治疗对放射性脑损伤(RE)患者MR-T_(1ρ)成像和脑结构MRI的影响。方法:选取医院收治的105例经病理确诊的肺腺癌合并RE患者,均予以BVZ治疗(5 mg/kg,2周/次),并按照放射治疗时间的不同将其分为治疗前组(33例)、治疗1年组(35例)和治疗>1年组(37例),3组均进行MR-T_(1ρ)成像和脑结构MRI,并获取相关影像学数据。采用单因素方差分析BVZ治疗过程中对RE患者的MR-T_(1ρ)成像和脑结构MRI的影响。结果:对比BVZ治疗前,BVZ治疗后肺腺癌合并RE患者MR-T_(1ρ)值主要呈现出升高→降低→升高或升高→升高→升高两种动态变化趋势;对比BVZ治疗前,肺腺癌合并RE患者BVZ治疗前后均存在多个脑区体积改变状态,且随BVZ治疗时间的后移,脑区数目逐渐增多,少有脑区体积缩小,差异有统计学意义(t=14.243,t=19.263;P<0.05)。结论:BVZ治疗肺腺癌合并RE患者会引起MR-T_(1ρ)值的动态变化,可减少和修复脑实质微观损伤。BVZ治疗可引起肺腺癌合并RE患者全脑多个脑区的体积改变,可改善神经元、血管损伤,提升机体免疫反应能力,有一定的临床应用价值。 | 王瑶 曲宝林 刘芳 杨微 马娜 杜乐辉 | 2021 | 中国医学装备2021，18，4： | 1 |
| 19 | 安罗替尼辅助同步放化疗治疗局部晚期食管癌的疗效及安全性显示文摘目的观察安罗替尼辅助同步放化疗治疗局部晚期食管癌的疗效及安全性。方法选取2021年6月—2022年1月九江市第一人民医院收治的80例局部晚期食管癌患者作为研究对象,根据治疗方法分为对照组和研究组,各40例。对照组接受同步放化疗治疗,研究组在对照组基础上联用安罗替尼治疗。2组均以3周为1个治疗周期,共治疗6个周期。比较2组实体瘤疗效、肿瘤标志物[癌胚抗原(CEA)、鳞状细胞癌抗原(SCCA)]、健康调查量表36(SF-36)评分、患者尊严量表(PDI)评分及不良反应。结果研究组客观缓解率高于对照组(85.00%vs.50.00%,χ^(2)=11.168,P=0.001)。治疗结束后,2组血清CEA、SCCA水平低于治疗前,且研究组低于对照组(P<0.01);2组SF-36评分高于治疗前,PDI评分低于治疗前,且研究组升高/降低幅度大于对照组(P<0.01)。研究组与对照组不良反应总发生率比较,差异无统计学意义(20.00%vs.35.00%,χ^(2)=2.257,P=0.133)。结论安罗替尼辅助同步放化疗治疗局部晚期食管癌的疗效较好,能够有效降低患者血清肿瘤标志物水平,提高患者的尊严水平及生活质量,且安全性较高。 | 陈辉 彭金娣 陈敏杰 | 2023 | 临床合理用药杂志2023，16，21： | 1 |
| 20 | ZNF292 suppresses proliferation of ESCC cells through ZNF292/SKP2/P27 signaling axis显示文摘Objective:Increasing evidence has demonstrated that ZNF292 plays a suppressive role in cancer,however,little is known about its function and exact mechanism in esophageal squamous cell carcinoma(ESCC).Methods:Bioinformatic analysis and immunohistochemistry(IHC)were performed to analyze the role of ZNF292 in affecting the prognosis of ESCC.Cell proliferation and colony formation ability assays were performed to analyze cell growth after inferring the expression of ZNF292.Flow cytometry was used to analyze changes in the cell cycle upon the depletion of ZNF292.Quantitative real-time polymerase chain reaction(q RT-PCR)and western blot analysis were used to determine the alteration of cell cycle related RNAs and proteins after knocking down ZNF292.MG-132,cycloheximide(CHX)treatment experiments were performed to analyze the change and half-life time of P27 after knockdown of ZNF292.Chromatin immunoprecipitation(Ch IP)and luciferase reporter assays were used to analyze the transcriptional regulation of SKP2 by ZNF292.Results:We report that low expression of ZNF292 is associated with poor prognosis,and ZNF292 emerges to be highly expressed in adjacent and normal tissues rather than tumor tissues in ESCC.Knockdown of ZNF292 significantly boosts cell growth and S phase entry in ESCC cells.ZNF292 depletion will decrease the expression and half-life time of P27,while knockdown of SKP2 will result in elevated expression of P27.ZNF292 can bind to the promoter region of SKP2,and knockdown of ZNF292 will boost the expression of SKP2.Conclusions:Knockdown of ZNF292 mediates G1/S cell cycle procession by activating SKP2/P27 signaling in ESCC cells.ZNF292 knockdown promotes SKP2 expression at the transcriptional level,thereby boosting P27 ubiquitin-degradation,and eventually facilitating the S phase entrance. | Wei Gong Jiancheng Xu Guangchao Wang Dan Li Qimin Zhan | 2021 | Chinese Journal of Cancer Research2021，33，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员